Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE: DTG+TAF+FTC vs DTG+TDF+FTC vs EFV+TDF+FTC in First-line HIV
NCT03122262Phase 3Completed
- Start
- Jan 2017
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dolutegravir and tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1) (3 arms). Primary endpoint: Proportion of patients with undetectable plasma HIV-1 RNA levels (< 50 copies/mL) at 48 weeks. Started Jan 2017; status: completed.
02
Drugs
dolutegravirtenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03122262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03122262.